Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
Bioequity EuropeBioequity Europe
Not Confirmed
Not Confirmed
04-06 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Arvo
Not Confirmed
Contact SupplierArvo
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Bioequity EuropeBioequity Europe
Industry Trade Show
Not Confirmed
04-06 May, 2026
Digital content
NEWS #PharmaBuzz
23 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/23/3279842/0/en/mbx-biosciences-to-host-in-person-and-virtual-obesity-day-on-may-11-2026-to-discuss-expanding-obesity-portfolio.html
03 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/03/3267994/0/en/MBX-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
12 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/12/3254562/0/en/MBX-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Corporate-Highlights.html
10 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/10/3252740/0/en/MBX-Biosciences-Appoints-Karen-Basbaum-as-Chief-Business-Officer.html
23 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/23/3242569/0/en/MBX-Biosciences-to-Participate-in-Upcoming-March-Investor-Conferences.html
11 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/11/3236234/0/en/MBX-Biosciences-to-Participate-in-Upcoming-Investor-Conferences.html
Drugs in Development
Details:
MBX 4291 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Lead Product(s): MBX 4291
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2025
Lead Product(s) : MBX 4291
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX 4291 Safety, Tolerability, PK/PD In Adults with Obesity
Details : MBX 4291 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 27, 2025
Details:
MBX 1416 is a Hormone drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Lead Product(s): MBX 1416
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 19, 2025
Lead Product(s) : MBX 1416
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Subcutaneous MBX 1416 In Postbariatric Hypoglycemia Patients
Details : MBX 1416 is a Hormone drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 19, 2025
Details:
MBX 4291 is a long-acting GLP1/GIP Receptor co-agonist prodrug, which is currently being evaluated for the treatment of obesity.
Lead Product(s): MBX 4291
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 16, 2025
Lead Product(s) : MBX 4291
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Submits IND for MBX 4291 to Treat Obesity with GLP1/GIP Co-Agonist
Details : MBX 4291 is a long-acting GLP1/GIP Receptor co-agonist prodrug, which is currently being evaluated for the treatment of obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 16, 2025
Details:
MBX 2109 (canvuparatide) is a long-acting PTH peptide prodrug which is currently being evaluated for the treatment of patients with hypoparathyroidism.
Lead Product(s): Canvuparatide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 03, 2025
Lead Product(s) : Canvuparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Completes Enrollment in Phase 2 Avail Trial for MBX 2109
Details : MBX 2109 (canvuparatide) is a long-acting PTH peptide prodrug which is currently being evaluated for the treatment of patients with hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 03, 2025
Details:
MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): MBX 1416
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2025
Lead Product(s) : MBX 1416
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Announces Positive Phase 1 Results for MBX 1416 in Hypoglycemia
Details : MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 07, 2025
Details:
MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): MBX 1416
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024
Lead Product(s) : MBX 1416
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MBX Biosciences Completes Phase 1 MBX 1416 Study for Post-Bariatric Hypoglycemia
Details : MBX 1416 is a long-acting GLP-1 receptor antagonist, which is currently being evaluated for the treatment of post-bariatric hypoglycemia.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 18, 2024
Details:
The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Lead Product(s): Canvuparatide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $187.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 16, 2024
Lead Product(s) : Canvuparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $187.7 million
Deal Type : Public Offering
MBX Biosciences Closes Upsized IPO, Underwriters Purchase Additional Shares
Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 16, 2024
Details:
The proceeds will advance the development of MBX 2109 and MBX 1416, two clinical programs, MBX 4291. MBX 2109 is designed as a potential long-acting hormone replacement therapy for hypoparathyroidism.
Lead Product(s): Canvuparatide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $163.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2024
Lead Product(s) : Canvuparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $163.2 million
Deal Type : Public Offering
MBX Biosciences Announces Pricing of Initial Public Offering
Details : The proceeds will advance the development of MBX 2109 and MBX 1416, two clinical programs, MBX 4291. MBX 2109 is designed as a potential long-acting hormone replacement therapy for hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 12, 2024
Details:
The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Lead Product(s): Canvuparatide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: $163.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 12, 2024
Lead Product(s) : Canvuparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $163.2 million
Deal Type : Public Offering
MBX Biosciences Announces Pricing of Initial Public Offering
Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 12, 2024
Details:
The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Lead Product(s): Canvuparatide
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering August 26, 2024
Lead Product(s) : Canvuparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
MBX files for IPO, Seeking Cash to Take Challenger to Ascendis' Yorvipath into Phase 3
Details : The company will advance its clinical-stage programs including MBX 2109, a long-acting PTH peptide prodrug in development for the treatment of hypoparathyroidism.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
August 26, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
